Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Movement Disorders topic
No spam. Unsubscribe anytime.
Advocates urge study of medication-induced movement disorders under Senate Bill 448
Summary
Testimony from the Movement Disorders Policy Coalition supported Senate Bill 448, which would direct the Oregon Health Authority to study tardive dyskinesia and other medication-induced movement disorders, develop educational materials for public safety personnel and issue a strategic plan by Dec. 31, 2025.
Senate Bill 4 48 would direct the Oregon Health Authority to study tardive dyskinesia and other medication-induced movement disorders, analyze screening and treatment barriers, create educational materials for law enforcement and public-safety professionals, and produce a strategic plan by Dec. 31, 2025, the committee heard on March 13.
Josie Cooper testified on behalf of the Movement Disorders Policy Coalition, a coalition of more than 20 organizations representing clinicians and patients with movement disorders. Cooper said the study would help identify opportunities to expand resources, improve screening and ensure equitable access to FDA-approved treatments for medication-induced movement disorders such as tardive dyskinesia. "Folks with TD experience involuntary, repetitive movements that can be painful and life altering," Cooper said. "They also often face stigma and barriers to care."
Committee staff summarized the bill’s operations to include an inventory of existing resources, analysis of barriers to diagnosis and treatment, outreach and training materials for public-safety professionals, and a required report and strategic plan to the Legislature by Dec. 31, 2025.
What the committee heard
- Advocates argued a state-level study would improve screening, diagnosis and treatment access and produce resources for clinicians, patients and public-safety personnel.
- Senator Lisa Reynolds (physician) asked clarifying questions about current barriers to treatment and training; advocates said while clinicians receive training, gaps in access, screening tools and equitable treatment persist for many patients.
Next steps
The committee closed the public hearing on SB 448 for the day. If advanced, the bill would direct OHA to produce the analysis, materials and the report within the stated deadline.
Ending: Patient and clinician advocates urged the committee to back SB 448 as a step toward identifying gaps and improving care for people with medication-induced movement disorders.
